115 related articles for article (PubMed ID: 15451944)
1. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes.
Kiess W; Raile K; Galler A; Kapellen T
Diabetes Care; 2004 Oct; 27(10):2567-8. PubMed ID: 15451944
[No Abstract] [Full Text] [Related]
2. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.
Plank J; Bodenlenz M; Sinner F; Magnes C; Görzer E; Regittnig W; Endahl LA; Draeger E; Zdravkovic M; Pieber TR
Diabetes Care; 2005 May; 28(5):1107-12. PubMed ID: 15855574
[TBL] [Abstract][Full Text] [Related]
3. Use of insulin glargine in Japanese patients with type 1 diabetes.
Yamamoto-Honda R; Takahashi Y; Yoshida Y; Hara Y; Kawai A; Kitazato H; Tanaka T; Kajio H; Kikuchi M; Akanuma Y; Noda M
Intern Med; 2007; 46(13):937-43. PubMed ID: 17603230
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy.
Hermansen K; Madsbad S; Perrild H; Kristensen A; Axelsen M
Diabetes Care; 2001 Feb; 24(2):296-301. PubMed ID: 11213882
[TBL] [Abstract][Full Text] [Related]
5. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
[TBL] [Abstract][Full Text] [Related]
6. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes.
Dailey G; Rosenstock J; Moses RG; Ways K
Diabetes Care; 2004 Oct; 27(10):2363-8. PubMed ID: 15451901
[TBL] [Abstract][Full Text] [Related]
7. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes.
Heise T; Nosek L; Rønn BB; Endahl L; Heinemann L; Kapitza C; Draeger E
Diabetes; 2004 Jun; 53(6):1614-20. PubMed ID: 15161770
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials.
Palmer AJ; Roze S; Valentine WJ; Smith I; Wittrup-Jensen KU
Curr Med Res Opin; 2004 Nov; 20(11):1729-46. PubMed ID: 15537473
[TBL] [Abstract][Full Text] [Related]
9. [Long-acting insulin analog, glargine, in the treatment of type 1 diabetes].
Tuomi T
Duodecim; 2004; 120(1):88-92. PubMed ID: 14976814
[No Abstract] [Full Text] [Related]
10. Optimization of evening insulin dose in patients using the short-acting insulin analog lispro.
Ahmed AB; Mallias J; Home PD
Diabetes Care; 1998 Jul; 21(7):1162-6. PubMed ID: 9653613
[TBL] [Abstract][Full Text] [Related]
11. A comparison of insulin detemir and neutral protamine Hagedorn (isophane) insulin in the treatment of diabetes: a systematic review.
Frier BM; Russell-Jones D; Heise T
Diabetes Obes Metab; 2013 Nov; 15(11):978-86. PubMed ID: 23551900
[TBL] [Abstract][Full Text] [Related]
12. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
Rosenstock J; Park G; Zimmerman J;
Diabetes Care; 2000 Aug; 23(8):1137-42. PubMed ID: 10937511
[TBL] [Abstract][Full Text] [Related]
13. Effect of subcutaneous insulin detemir on glucose flux, lipolysis and electroencephalography in type 1 diabetes.
Herring R; Knight R; Shojaee-Moradie F; Johnsen S; Umpleby AM; Jackson N; Jones R; Dijk DJ; Russell-Jones DL
Diabetes Obes Metab; 2015 Nov; 17(11):1100-3. PubMed ID: 26272173
[TBL] [Abstract][Full Text] [Related]
14. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
[TBL] [Abstract][Full Text] [Related]
15. Cerebral blood flow and glucose metabolism in appetite-related brain regions in type 1 diabetic patients after treatment with insulin detemir and NPH insulin: a randomized controlled crossover trial.
van Golen LW; IJzerman RG; Huisman MC; Hensbergen JF; Hoogma RP; Drent ML; Lammertsma AA; Diamant M
Diabetes Care; 2013 Dec; 36(12):4050-6. PubMed ID: 24130356
[TBL] [Abstract][Full Text] [Related]
16. Insulin detemir: a long-acting insulin product.
Jones MC; Patel M
Am J Health Syst Pharm; 2006 Dec; 63(24):2466-72. PubMed ID: 17158694
[TBL] [Abstract][Full Text] [Related]
17. Nighttime insulin kinetics and glycemic control in type 1 diabetes patients following administration of an intermediate-acting lispro preparation.
Janssen MM; Casteleijn S; Devillé W; Popp-Snijders C; Roach P; Heine RJ
Diabetes Care; 1997 Dec; 20(12):1870-3. PubMed ID: 9405909
[TBL] [Abstract][Full Text] [Related]
18. [Long-acting insulins in the treatment of type 2 diabetes: a hard choice].
Liebl A
MMW Fortschr Med; 2015 Apr; 157(7):65-8. PubMed ID: 26012462
[No Abstract] [Full Text] [Related]
19. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus.
Chapman TM; Perry CM
BioDrugs; 2005; 19(1):67-9. PubMed ID: 15691219
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
